Flputnam Investment Management Co. Has $2.17 Million Stock Position in Zoetis Inc. $ZTS

Flputnam Investment Management Co. boosted its stake in Zoetis Inc. (NYSE:ZTS) by 1,595.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,218 shares of the company’s stock after acquiring an additional 28,436 shares during the period. Flputnam Investment Management Co.’s holdings in Zoetis were worth $2,171,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ZTS. J. Stern & Co. LLP lifted its position in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares during the period. Norges Bank bought a new position in Zoetis during the fourth quarter worth $734,425,000. Flossbach Von Storch SE bought a new position in Zoetis during the second quarter worth $302,601,000. BlackRock Inc. lifted its holdings in Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after buying an additional 3,845,869 shares during the period. Finally, Ruane Cunniff & Goldfarb L.P. bought a new stake in Zoetis during the first quarter valued at $286,660,000. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of recent analyst reports. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. UBS Group reduced their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. HSBC cut their target price on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Finally, Barclays cut their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $107.43.

Zoetis Stock Up 0.1%

Zoetis stock opened at $77.45 on Monday. The firm has a market capitalization of $32.00 billion, a price-to-earnings ratio of 12.76, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73. The firm’s fifty day moving average price is $75.57 and its two-hundred day moving average price is $95.40. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $156.49. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the firm posted $1.76 earnings per share. The firm’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.